Highlights of ESH-iCMLf 28th Annual John Goldman Conference on CML
Hear from Professor Daniela Krause and Professor Jorge Cortes about highlights from the 2025 ESH-iCMLf 28th Annual John Goldman Conference on CML
Biological overview
Expert
Professor Daniela Krause
Director of the Institute of Transfusion Medicine at the University of Mainz (Germany)
Program
Overview of significant biological aspects presented during the conference, including:
- Stem cells, clonal hematopoiesis and genetic mutations
- Metabolism and immune mechanisms in CML
- Blast crisis and disease progression
- Bone marrow microenvironment
- Minimal residual disease and treatment-free remission
- Novel therapies and predictive markers
- Emerging research: Glycobiology and cell death mechanisms
- Special lectures: Pediatric CML, TKI resistance and transplantation
Clinical Overview
Expert
Professor Jorge Cortes
Georgia Cancer Centre, Augusta (USA)
Program
Overview of significant clinical aspects presented during the conference, including:
- Predictors of treatment-free remission
- ASC4START: Asciminib versus nilotinib
- Advances in minimal residual disease monitoring
- Genetic abnormalities and disease progression
- Treatment-free remission: Benefits and challenges
- Novel therapies: ELVN-001, ASC4OPT (Asciminib dosing strategies) and TGRX678
- Advances in pediatric CML
- New TFR strategies: NAUT (2 nd and subsequent TFR attempts) and HALF (stepwise
dose reduction before discontinuation) studies - Advancing CML care in Ethiopia – iCMLf Prize 2026